The National Medical Insurance Bureau issued the national procurement renewal document: no "only bargaining, no quantity"!

Organize: slowly

So far, 5 batches of volume procurement have been carried out, covering a total of 218 drugs

Ranging, 4+7 volume purchases will be implemented in the first half of 2019.

On November 4, the National Medical Insurance Administration issued the "Notice on Doing a Good Job in the Continuation of the State-Organized Drug Centralized Purchase Agreement after the Expiry" to consolidate the results of the state-organized drug centralized procurement reform and achieve a smooth continuation after the expiration of the procurement agreement

The "Notice" pointed out that, in principle, all national organizations should continue to carry out centralized procurement after the expiration of the drug procurement agreement, and it is not allowed to "negotiate only without supplying the quantity"

Regarding the quantity of drugs purchased by centralized procurement, the "Notice" proposes that medical institutions should report the demand for drugs to be purchased based on factors such as the actual use of the previous year, the status of clinical use, and the progress of medical technology

In the continuation of the classification development, the "Notice" proposes to focus on maintaining the stability of the market and clinical medication, comprehensively consider the various factors of the enterprise and product, and determine the selected enterprises and the selected prices through inquiry, bidding, and comprehensive evaluation

First of all, for the products selected in the previous round of centralized procurement, in principle, the inquiry will be carried out on the basis of a stable price level and clinical use

Secondly, if the inquiry is unsuccessful, or the result of the selection was produced in the last round of centralized procurement, or the actual sales price of the non-selected products in the current market is significantly lower than the lowest selected price in the province in the previous round of centralized procurement and there is actual supply, The selected companies and the selected prices can be reproduced through bidding

For provinces with high demand or high supply guarantee requirements, the same product is encouraged to be selected by multiple companies, and the price difference between different selected companies should be fair and reasonable

In addition, in response to previous penalties for winning bids for failing to supply the agreed procurement volume in accordance with the agreement, the "Notice" also made provisions on "strengthening credit and performance evaluation", "improving supporting policies", and "strengthening performance supervision".

One is to strengthen credit and performance evaluation

The second is to improve supporting policies

The third is to strengthen supervision of compliance

Reference source: official website of the National Medical Insurance Administration